Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...
Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...
Regeneron (NASDAQ: REGN )'s flagship eye drug franchise, consisting of EYLEA HD and EYLEA, saw U.S. net sales increase 2% to ...
Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...
The first task for the accelerator will be to address the needs of patients with atopic dermatitis – a key indication for Sanofi's blockbuster immunology medicine Dupixent (dupilumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback